Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > GKOS Glaukos > Key Indicators
GKOS Glaukos
47.820
-0.840-1.73%
Post Mkt Price
47.8200.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
27.04% 135.2099 -5.19% 93.0514 5.99% 107.9916 -24.93% 117.4128
Receivable Turnover(T)
-5.71% 8.1391 -11.35% 7.8346 13.39% 8.2163 40.06% 8.4611
Inventory Turnover(T)
-27.29% 2.5462 -20.56% 2.9611 -4.94% 3.3546 9.26% 3.4326
Fixed Assets Turnover(T)
-24.58% 1.9009 -22.07% 2.0642 -3.77% 2.2291 1.31% 2.4339
Total Asset Rate(T)
-3.76% 0.2749 -0.26% 0.2779 7.40% 0.2831 15.99% 0.2861
ROIC
-226.55% -8.606% -42.19% -5.959% 65.86% -2.462% 67.18% -4.274%
ROE
-156.50% -15.589% -0.53% -9.732% 65.24% -4.674% 55.96% -7.906%
ROA
-131.97% -8.647% 9.12% -5.378% 70.87% -2.675% 63.43% -4.826%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- -66.00% -6.118%
ROA 5 Year Average
-- -- -- -- -- -- -62.00% -4.405%
Average 5 Years ROIC
-- -- -- -- -- -- -50.09% -4.955%
Profitability Ratios TTM
Gross Margin
-0.65% 75.912% 2.71% 76.716% 13.34% 77.170% 30.58% 77.339%
Operating Margin
-76.50% -33.856% -85.75% -32.538% 30.32% -24.266% 61.06% -21.384%
Net Margin
-141.02% -31.455% 8.88% -19.354% 72.88% -9.447% 68.47% -16.868%
EBITDA Margin
-555.06% -0.1413% 41.51% -0.024% 139.40% 0.0713% 98.65% -0.005%
R & D Expense Ratio
21.36% 43.580% 38.25% 44.780% 15.47% 39.720% -0.55% 37.750%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- 327.11% 68.010% 362.82% 63.971% 60.51% 65.124%
Total Assets to Common Equity
-- -- 2.65% 183.346% 1.52% 176.060% 18.67% 178.778%
Debt to Asset Ratio
-- -- 6.72% 68.010% 4.65% 63.971% 60.51% 65.124%
Current Ratio
-- -- 382.86% 6.7776 525.09% 8.8352 -18.77% 7.6724
Quick Ratio
-- -- 370.92% 6.1464 511.93% 8.098 -20.30% 7.0626
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- 43.34% 17.491%
Revenue CAGR(5Y)
-- -- -- -- -- -- -19.13% 20.779%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
CEO: Mr. Thomas W. Burns
Market: NYSE
Listing Date: 06/25/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist